Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review

Lung Squamous Cell Carcinoma with EML4-ALK Fusion and TP53 Co-mutation 
Treated with Ensartinib: A Case Report and Literature Review

Lung squamous cell carcinoma (LSCC) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases and is the second most common histological type of lung cancer. Anaplastic lymphoma kinase (ALK)-positive NSCLC accounts for only 2%-5% of all NSCLC cases, and is almost exclusively detecte...

Full description

Bibliographic Details
Main Authors: Donglai LV, Chunwei XU, Chong WANG, Qiuju SANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-01-01
Series:Chinese Journal of Lung Cancer
Subjects:
alk fusion gene
lung neoplasms
tp53
ensartinib
lorlatinib
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.03

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.03

Similar Items